← Leaderboards
Cherie-Ann O Nathan
Louisiana State Univ Hsc Shreveport
$3,675,170
Attributed
$4,646,948
Total exposure
4
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $399.8K · FY2005–22$500K$375K$250K$125K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
Funding mix
By agency
NIH$4,646,948 · 4
By mechanism
R01$4,186,482 · 2
R21$460,466 · 2
Top collaborators
- John Digiovanni5 shared
Others in their field
Top investigators on “Tumor”
- David Heimbrook · Leidos Biomedical Research, Inc.$636,492,067
- Leonard Freedman · Leidos Biomedical Research, Inc.$360,535,780
- Gregory H Reaman · National Childhood Cancer Foundation$208,276,509
- Richard K. Wilson · Washington University$203,917,615
- Norman Wolmark · Nsabp Foundation, Inc.$177,323,696
- Ronald T Mitsuyasu · University Of California Los Angeles$138,361,819
Research focus
TumorBaseMalignant NeoplasmsIn VitroTissuesTumor ProgressionResponsePathway InteractionsPhosphorylationPecam1 GeneSurgical MarginsMalignant Squamous Cell NeoplasmExcisionRecurrenceHead And Neck Cancer PatientApoptosisHead And Neck StructureCancer RecurrenceHistologicClinical TrialsHead And Neck Squamous Cell CarcinomaHead And Neck CancerMouse ModelMtor Inhibitor
Grant awards (19)
Targeting Fibroblast Growth Factor Receptor-2b in prevention and treatment of cutaneous Squamous cell carcinoma.$383,159
R01 · FY2022 · CA · contact PI
Targeting Fibroblast Growth Factor Receptor-2b in prevention and treatment of cutaneous Squamous cell carcinoma.$386,483
R01 · FY2021 · CA · contact PI
Targeting Fibroblast Growth Factor Receptor-2b in prevention and treatment of cutaneous Squamous cell carcinoma.$388,890
R01 · FY2020 · CA · contact PI
Targeting Fibroblast Growth Factor Receptor-2b in prevention and treatment of cutaneous Squamous cell carcinoma.$385,203
R01 · FY2019 · CA · contact PI
Targeting Fibroblast Growth Factor Receptor-2b in prevention and treatment of cutaneous Squamous cell carcinoma.$399,821
R01 · FY2018 · CA · contact PI
Multi-institutional trial: adjuvant mTOR targeted therapy$215,731
R01 · FY2015 · CA · contact PI
Multi-institutional trial: adjuvant mTOR targeted therapy$209,259
R01 · FY2014 · CA · contact PI
Multi-institutional trial: adjuvant mTOR targeted therapy$200,308
R01 · FY2013 · CA · contact PI
Multi-institutional trial: adjuvant mTOR targeted therapy$215,731
R01 · FY2012 · CA · contact PI
Multi-institutional trial: adjuvant mTOR targeted therapy$206,126
R01 · FY2011 · CA · contact PI
Microgranular Curcumin Biomarker Trial in Head and Neck Squamous Cell Carcinoma$150,615
R21 · FY2011 · CA · contact PI
Microgranular Curcumin Biomarker Trial in Head and Neck Squamous Cell Carcinoma$187,137
R21 · FY2010 · CA · contact PI
Multi-institutional trial: molecular analysis of margins$214,028
R01 · FY2009 · CA · contact PI
Multi-institutional trial: molecular analysis of margins$103,502
R01 · FY2009 · CA · contact PI
Multi-institutional trial: molecular analysis of margins$213,420
R01 · FY2008 · CA · contact PI
Multi-institutional trial: molecular analysis of margins$212,005
R01 · FY2007 · CA · contact PI
Multi-institutional trial: molecular analysis of margins$223,716
R01 · FY2006 · CA · contact PI
Multi-institutional trial: molecular analysis of margins$229,100
R01 · FY2005 · CA
MOLECULAR ANALYSIS OF SURGICAL MARGINS WITH EIF4E IN CAN$122,714
R21 · FY2000 · CA